SCHEMBL2459795

SCHEMBL2459795

N#Cc1ccccc1COc1cccc(C2=NC(C3=CC=C3)=C3C=NC=C[N+]23N)c1

nearest known ligand 0.33

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
GRIN1 Q05586 1/20 0.33
GRIN2B Q13224 1/20 0.33
MAOB P27338 1/20 0.33
PLAU P00749 1/20 0.32
SPHK2 Q9NRA0 1/20 0.32
SPHK1 Q9NYA1 1/20 0.32
FFAR1 O14842 1/20 0.31
KCNH2 Q12809 1/20 0.31
PRMT5 O14744 1/20 0.31
WDR77 Q9BQA1 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2459926 0.87 NR1H2 (0.39) MAOB
SCHEMBL2460739 0.87 EGFR (0.38) MAOBKCNH2
SCHEMBL2460721 0.87 PTGER1 (0.35) FFAR1
SCHEMBL2460704 0.87 PARP10 (0.31)
SCHEMBL2460315 0.86 NPC1 (0.38) SPHK2SPHK1FFAR1
SCHEMBL2460142 0.85 CYP11B1 (0.39) MAOBSPHK2SPHK1
SCHEMBL2460200 0.85 MAOB (0.37) MAOB
SCHEMBL2457154 0.85 CTSA (0.31) MAOB
SCHEMBL2462400 0.84 IGF1R (0.35)
SCHEMBL2459871 0.84 CFD (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1675860-B1 IMIDAZO[1,5-A]PYRAZINES AS TYROSINE KINASE INHIBITORS OSI PHARM INC (US) 2011-09-21 EP claimed
US-7459554-B2 Imidazopyrazine tyrosine kinase inhibitors OSI PHARMACEUTICALS, INC. (US) 2008-12-02 US claimed
US-20080227788-A9 IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS BECK PATRICIA A 2008-09-18 US claimed
US-20060084654-A1 Imidazopyrazine tyrosine kinase inhibitors ACERTA PHARMA B.V. (NL) 2006-04-20 US claimed
EP-1675860-B1 IMIDAZO[1,5-A]PYRAZINES AS TYROSINE KINASE INHIBITORS OSI PHARM INC (US) 2011-09-21 EP disclosed
US-20090181940-A1 Imidazopyrazine Tyrosine Kinase Inhibitors OSI PHARMACEUTICALS, INC. 2009-07-16 US disclosed
US-7459554-B2 Imidazopyrazine tyrosine kinase inhibitors OSI PHARMACEUTICALS, INC. (US) 2008-12-02 US disclosed
US-20080227788-A9 IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS BECK PATRICIA A 2008-09-18 US disclosed
EP-1675860-A2 IMIDAZO[1,5-A]PYRAZINE TYROSINE KINASE INHIBITORS OSI Pharmaceuticals, Inc. (US) 2006-07-05 EP disclosed
US-20060084654-A1 Imidazopyrazine tyrosine kinase inhibitors ACERTA PHARMA B.V. (NL) 2006-04-20 US disclosed
WO-2005037836-A2 IMIDAZO ‘1, 5 - A ! PYRAZINE TYROSINE KINASE INHIBITORS OSI PHARMACEUTICALS, INC. (US) 2005-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080227788-A9 IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS IGF1R, IRS1, IGFBP1 GRIN1 1322/4885GRIN2B 2194/4885MAOB 1546/4885
US-20060084654-A1 Imidazopyrazine tyrosine kinase inhibitors IGF1R, IRS1, IGFBP1 GRIN1 1322/4885GRIN2B 2194/4885MAOB 1546/4885
US-20090181940-A1 Imidazopyrazine Tyrosine Kinase Inhibitors IGF1R, IRS1, IGFBP1 GRIN1 1322/4885GRIN2B 2194/4885MAOB 1546/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.